Your browser doesn't support javascript.
loading
Reply to Aitken et al., "Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC ß-Lactamases?"
Cheng, Lucy; Nelson, Brian C; Mehta, Monica; Shi, Qiuhu; Gomez-Simmonds, Angela; Uhlemann, Anne-Catrin.
Affiliation
  • Cheng L; Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
  • Nelson BC; NewYork-Presbyterian Hospital, New York, New York, USA.
  • Mehta M; NewYork-Presbyterian Hospital, New York, New York, USA.
  • Shi Q; New York Medical College, Valhalla, New York, USA.
  • Gomez-Simmonds A; Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
  • Uhlemann AC; Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA au2110@columbia.edu.
Antimicrob Agents Chemother ; 61(9)2017 09.
Article in En | MEDLINE | ID: mdl-28839083
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperacillin / Enterobacteriaceae Language: En Journal: Antimicrob Agents Chemother Year: 2017 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperacillin / Enterobacteriaceae Language: En Journal: Antimicrob Agents Chemother Year: 2017 Document type: Article Affiliation country: United States Country of publication: United States